Publication: SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
dc.contributor.author | Rueda Domínguez, Antonio | |
dc.contributor.author | Cirauqui, Beatriz | |
dc.contributor.author | García Castaño, Almudena | |
dc.contributor.author | Alvarez Cabellos, Ruth | |
dc.contributor.author | Carral Maseda, Alberto | |
dc.contributor.author | Castelo Fernández, Beatriz | |
dc.contributor.author | Iglesias Rey, Leticia | |
dc.contributor.author | Rubió-Casadevall, Jordi | |
dc.contributor.author | Arrazubi, Virginia | |
dc.contributor.author | Mesía, Ricard | |
dc.date.accessioned | 2023-05-03T13:59:10Z | |
dc.date.available | 2023-05-03T13:59:10Z | |
dc.date.issued | 2022-03-18 | |
dc.description.abstract | Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time. | |
dc.identifier.doi | 10.1007/s12094-022-02814-x | |
dc.identifier.essn | 1699-3055 | |
dc.identifier.pmc | PMC8986714 | |
dc.identifier.pmid | 35303267 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986714/pdf | |
dc.identifier.unpaywallURL | https://link.springer.com/content/pdf/10.1007/s12094-022-02814-x.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/21108 | |
dc.issue.number | 4 | |
dc.journal.title | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | |
dc.journal.titleabbreviation | Clin Transl Oncol | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.organization | Instituto de Investigación Biomédica de Málaga-IBIMA | |
dc.page.number | 670-680 | |
dc.pubmedtype | Journal Article | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Clinical Practice Guidelines | |
dc.subject | Diagnosis | |
dc.subject | Follow-up | |
dc.subject | Nasopharyngeal cancer | |
dc.subject | Treatment | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Nasopharyngeal Carcinoma | |
dc.subject.mesh | Nasopharyngeal Neoplasms | |
dc.title | SEOM-TTCC clinical guideline in nasopharynx cancer (2021). | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 24 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1